BioCentury | Feb 27, 2020
Product Development

Amgen’s plan for holding its competitive edge in two hot cancer spaces

Amgen has a first-mover advantage in two of the hottest areas of cancer R&D -- KRAS and bispecific antibodies -- and it’s using a combination of rapid clinical development and innovative trial designs to maintain...
BioCentury | Feb 7, 2020
Emerging Company Profile

Led by Bluestone, Sonoma launches to turn Tregs against autoimmunity

Founded by a team of T cell biology pioneers including the Parker Institute’s Jeffrey Bluestone, Sonoma Biotherapeutics launched Thursday with a $40 million series A round to develop Treg-based cell therapies for autoimmune and neurodegenerative...
BC Extra | Dec 17, 2019
Company News

Management Tracks: Dynavax, Merus name CEOs; plus Grail hires a commercial lead, Seres, Zentalis, Nimbus and more

Dynavax Technologies Corp. (NASDAQ:DVAX) named Ryan Spencer as CEO and David Novack president and COO. Spencer succeeds Edward Gray, who retired in August. Both Spencer and Novack had been interim co-presidents since May, when the...
BC Extra | Nov 1, 2019
Financial News

Foresite launches incubator aimed at meshing data science with healthcare

With its newly launched incubator, Foresite will provide its companies access to a holistic data set and analytical tools to explore how data can drive the development of personalized medicine across broad diseases. The incubator,...
BC Innovations | Nov 1, 2019
Product Development

Adrenomed looks beyond immune modulators for sepsis, aims for shock prevention

By targeting a new mechanism further downstream in the sepsis pathway than previous approaches, Adrenomed thinks it can escape the graveyard that has sunk drug development in the indication. Its approach hinges on preventing the...
BioCentury | Oct 17, 2019
Emerging Company Profile

Parker Institute’s ArsenalBio launches with $85M to build cell engineering war chest

ArsenalBio launched Thursday with $85 million in a series A round to combine the technologies of its six Parker Institute co-founders into a suite of tools the company thinks could overcome key hurdles to cell...
BC Extra | Oct 9, 2019
Company News

GSK partners with Lyell to bring gene, cell therapies into solid tumors

As GSK looks to expand its cell and gene therapy pipeline, the pharma has partnered with Lyell to take the modalities into solid tumors by improving T cell functionality and manufacturing. Lyell Immunopharma Inc. is...
BC Extra | Oct 8, 2019
Company News

Management tracks: BioMarin's first chief scientific strategy officer; plus Ascletis, Grail, Aerie and more

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) promoted Lon Cardon to the newly created role of chief scientific strategy officer from CSO. Prior to BioMarin, Cardon was SVP of alternative discovery and development and head of target sciences...
BioCentury | Oct 4, 2019
Finance

Selectivity sets off $37M series A for mTOR company Aeovian

Preclinical selectivity data for Aeovian’s mTORC1 inhibitor prompted venBio and Sofinnova Investments to co-lead the biotech’s $37 million series A after long eyeing the space. “mTORC1 selective inhibition has been a Holy Grail target in...
BC Extra | Sep 19, 2019
Preclinical News

Sept. 19 Preclinical Quick Takes: Celsius' single-cell analysis; plus Merck's RSV therapy, glial cell transplant and methylation profiles for tumors

Celsius gets three single-cell analysis partners  Through separate deals, Celsius Therapeutics Inc. partnered with the Parker Institute for Cancer Immunotherapy, Institut Gustave-Roussy and University Health Network to apply its single-cell genomics platform, which includes machine-learning...
Items per page:
1 - 10 of 170